Compass trials mark a milestone moment for the psychedelics sector

July 21, 2025

12 min episode · 2 min read

Kabir Nath

Episode

12 min

Read time

2 min

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Phase Three Timeline: Compass has three sequential phase three readouts scheduled within fifteen to eighteen months: six-week primary endpoint data arriving next month, twenty-six-week data from study one, and twenty-six-week data from study two by end of 2026, each representing the largest psychedelic RCT ever conducted.
✓Treatment Model Distinction: COMP360 requires only one or two administrations rather than daily dosing. Therapists present during sessions are trained specifically to remain passive and non-interventional, functioning as safety monitors rather than active therapists, reducing the specialized labor burden compared to traditional psychedelic-assisted therapy models.
✓Reimbursement Pathway: FDA approval is the prerequisite for accessing CMS, Medicare, Medicaid, VA, and DOD reimbursement. Investors and stakeholders tracking commercial viability should monitor FDA designation progress as the direct gateway to government payer negotiations, not just clinical efficacy data.
✓PTSD Pipeline Expansion: Compass is extending COMP360 into PTSD, where only two decades-old drugs hold approval and none are actively marketed. The civilian PTSD population substantially exceeds the military population, and the same psychiatrists treating TRD also treat PTSD, creating strategic and operational alignment.

What It Covers

Compass Pathways CEO Kabir Nath discusses COMP360, a psilocybin-based treatment for treatment-resistant depression, as the company prepares three phase three trial readouts over the next fifteen to eighteen months, marking the first classic psychedelic to reach this stage.

Key Questions Answered

•Phase Three Timeline: Compass has three sequential phase three readouts scheduled within fifteen to eighteen months: six-week primary endpoint data arriving next month, twenty-six-week data from study one, and twenty-six-week data from study two by end of 2026, each representing the largest psychedelic RCT ever conducted.
•Treatment Model Distinction: COMP360 requires only one or two administrations rather than daily dosing. Therapists present during sessions are trained specifically to remain passive and non-interventional, functioning as safety monitors rather than active therapists, reducing the specialized labor burden compared to traditional psychedelic-assisted therapy models.
•Reimbursement Pathway: FDA approval is the prerequisite for accessing CMS, Medicare, Medicaid, VA, and DOD reimbursement. Investors and stakeholders tracking commercial viability should monitor FDA designation progress as the direct gateway to government payer negotiations, not just clinical efficacy data.
•PTSD Pipeline Expansion: Compass is extending COMP360 into PTSD, where only two decades-old drugs hold approval and none are actively marketed. The civilian PTSD population substantially exceeds the military population, and the same psychiatrists treating TRD also treat PTSD, creating strategic and operational alignment.

Notable Moment

Unlike antidepressants that merely reduce symptoms, Nath describes how some psilocybin patients report full remission of serious depression for extended periods — a qualitatively different outcome that conventional psychiatric treatments have not historically achieved.

Know someone who'd find this useful?